Atlantanews Online

DelveInsight Business Research LLP

“Pulmonary Hypertension Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Hypertension Market.

The Pulmonary Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pulmonary Hypertension Pipeline Report:

• Companies across the globe are diligently working toward developing novel Pulmonary Hypertension treatment therapies with a considerable amount of success over the years. 

• Pulmonary Hypertension companies working in the treatment market are  Alterras Therapeutics, Topadur Pharma, Centessa Pharmaceuticals, Ribomic, ATXA Therapeutics, Aerami Therapeutic, PhaseBio Pharmaceuticals, Ethyl Altavant Sciences, Respira Therapeutics, Pharmosa Biopharm, Merck, and others, are developing therapies for the Pulmonary Hypertension treatment 

• Emerging Pulmonary Hypertension therapies such as – ALT 001, TOP V122, MGX292, RBM-011, NTP42, AER-901, Pemziviptadil, Rodatristat, RT234 Respira, L606, Sotatercept, and others are expected to have a significant impact on the Pulmonary Hypertension market in the coming years.   

• In December 2021, Acceleron Pharma began a Phase 3 randomised, double-blind, placebo-controlled study to assess Sotatercept’s efficacy in participants with pulmonary arterial hypertension (PAH) who were at high risk of mortality and had WHO Functional Class (FC)III or FCIV

• In January 2021, To compare the effectiveness and safety of Sotatercept vs a placebo when added to background pulmonary arterial hypertension (PAH) therapy for the treatment of PAH, Acceleron Pharma started a Phase 3 randomised, double-blind, placebo-controlled research

• In March 2022, To assess Sotatercept’s efficacy when combined with background pulmonary arterial hypertension (PAH) therapy in newly diagnosed intermediate- and high-risk PAH patients, Acceleron Pharma started a Phase 3 randomised, double-blind, placebo-controlled research. The experiment is presently accepting applicants and is anticipated to have 662 participants by June 2028

• In October 2022, Sotatercept, an investigational activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein being evaluated as an adjunct to stable background therapy for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1), showed promise in the pivotal Phase 3 STELLAR trial, according to Merck (NYSE: MRK)

Pulmonary Hypertension Overview

Elevated pulmonary vascular resistance is a defining characteristic of the broad group of illnesses known as pulmonary hypertension. Patients frequently exhibit vague symptoms such as increasing weakness and dyspnea with exertion. The management of symptoms and the therapy of underlying disorders are the main goals of treatment for the progressive disease known as pulmonary hypertension.

Get a Free Sample PDF Report to know more about Pulmonary Hypertension Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

Emerging Pulmonary Hypertension Drugs Under Different Phases of Clinical Development Include:

• ALT 001: Alterras Therapeutics

• TOP V122: Topadur Pharma

• MGX292: Centessa Pharmaceuticals

• RBM-011: Ribomic

• NTP42: ATXA Therapeutics

• AER-901: Aerami Therapeutic

• Pemziviptadil: PhaseBio Pharmaceuticals

• Rodatristat: Ethyl Altavant Sciences

• RT234 Respira: Respira Therapeutics

• LIQ861: Liquidia Technologies

• Sotatercept: Acceleron Pharma

• L606: Pharmosa Biopharm

• Sotatercept: Merck

Route of Administration

Pulmonary Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

Pulmonary Hypertension Pipeline Therapeutics Assessment

• Pulmonary Hypertension Assessment by Product Type

• Pulmonary Hypertension By Stage and Product Type

• Pulmonary Hypertension Assessment by Route of Administration

• Pulmonary Hypertension By Stage and Route of Administration

• Pulmonary Hypertension Assessment by Molecule Type

• Pulmonary Hypertension by Stage and Molecule Type

DelveInsight’s Pulmonary Hypertension Report covers around 55+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Pulmonary Hypertension product details are provided in the report. Download the Pulmonary Hypertension pipeline report to learn more about the emerging Pulmonary Hypertension therapies

Some of the key companies in the Pulmonary Hypertension Therapeutics Market include:

Key companies developing therapies for Pulmonary Hypertension are – United Therapeutics Corporation, Bayer, Gilead Sciences, Inc., Johnson & Johnson, Viatris Inc., GlaxoSmithKline, Sandoz Inc. (Novartis), Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., and others.

Pulmonary Hypertension Pipeline Analysis:

The Pulmonary Hypertension pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Hypertension with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Hypertension Treatment.

• Pulmonary Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Pulmonary Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Hypertension market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pulmonary Hypertension drugs and therapies

Pulmonary Hypertension Pipeline Market Drivers

• Rising prevalence of Pulmonary Hypertension worldwide, increasing investment in healthcare infrastructure, robust Drug pipeline, and new product combinations are some of the important factors that are fueling the Pulmonary Hypertension Market.

Pulmonary Hypertension Pipeline Market Barriers

• However, high cost associated with the treatment of Pulmonary Hypertension, lack of awareness among people in developing countries, and other factors are creating obstacles in the Pulmonary Hypertension Market growth.

Scope of Pulmonary Hypertension Pipeline Drug Insight    

• Coverage: Global

• Key Pulmonary Hypertension Companies: Alterras Therapeutics, Topadur Pharma, Centessa Pharmaceuticals, Ribomic, ATXA Therapeutics, Aerami Therapeutic, PhaseBio Pharmaceuticals, Ethyl Altavant Sciences, Respira Therapeutics, Pharmosa Biopharm, Merck, and others

• Key Pulmonary Hypertension Therapies: ALT 001, TOP V122, MGX292, RBM-011, NTP42, AER-901, Pemziviptadil, Rodatristat, RT234 Respira, L606, Sotatercept, and others

• Pulmonary Hypertension Therapeutic Assessment: Pulmonary Hypertension current marketed and Pulmonary Hypertension emerging therapies

• Pulmonary Hypertension Market Dynamics: Pulmonary Hypertension market drivers and Pulmonary Hypertension market barriers 

Request for Sample PDF Report for Pulmonary Hypertension Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting